Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

KDM6A Regulates Immunogenicity of Multiple Myeloma (ATAC-seq)

ABSTRACT: KDM6A Regulates Immunogenicity of Multiple Myeloma (ATAC-seq)

PROVIDER: PRJNA1023292 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR26260928_1.fastq.gz	Fastqsanger.gz
	SRR26260928_2.fastq.gz	Fastqsanger.gz
	SRR26260929_1.fastq.gz	Fastqsanger.gz
	SRR26260929_2.fastq.gz	Fastqsanger.gz
	SRR26260930_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

KDM6A Regulates Immunogenicity of Multiple Myeloma

Project description:KDM6A Regulates Immunogenicity of Multiple Myeloma

| PRJNA1023289 | ENA

KDM6A Regulates Immunogenicity of Multiple Myeloma (ChIP-seq)

Project description:KDM6A Regulates Immunogenicity of Multiple Myeloma (ChIP-seq)

| PRJNA1023291 | ENA

KDM6A Regulates Immunogenicity of Multiple Myeloma (RNA-seq)

Project description:KDM6A Regulates Immunogenicity of Multiple Myeloma (RNA-seq)

| PRJNA1023293 | ENA

KDM6A Regulates Immunogenicity of Multiple Myeloma (ATAC-seq)

Project description:We created isogenic mutiple myeloma cell lines disrupted for KDM6A using CRISPR-mediated editing.

2024-10-01 | GSE244509 | GEO

KDM6A Regulates Immunogenicity of Multiple Myeloma (ChIP-seq)

Project description:We created isogenic mutiple myeloma and mouse embryonic fibroblast cell lines disrupted for KDM6A using CRISPR editing and Cre-mediated deletion. To detect KDM6A we inserted a dual HA tag sequence into the C-terminal of KDM6A by CRISPR-mediated editing. We also created one isogenic cell line harboring a jmjD-dead KDM6A where 2 amino acids essential for KDM6A enzymatic activity, H1146 and E1148 , were replaced with alanine residues

2024-10-01 | GSE244510 | GEO

KDM6A Regulates Immunogenicity of Multiple Myeloma (RNA-seq)

Project description:We created isogenic mutiple myeloma and mouse embryonic fibroblast cell lines disrupted for KDM6A using CRISPR editing and Cre-mediated deletion.

2024-10-01 | GSE244511 | GEO

Human Multiple Myeloma ATAC

Project description:Human Multiple Myeloma ATAC. This series contains the ATAC-seq data for Human Multiple Myeloma patients.

| PRJEB28803 | ENA

ATAC-seq of Multiple Myeloma

Project description:ATAC-seq of Multiple Myeloma

| PRJNA705686 | ENA

ATAC-seq of Multiple Myeloma

Project description:Purpose: Multiple myeloma is a malignancy of plasma cells. Extensive genetic and transcriptional characterization of myeloma has identified subtypes with prognostic and therapeutic implications. In contrast, relatively little is known about the myeloma epigenome. Experimental Design: CD138+CD38+ myeloma cells were isolated from fresh bone marrow aspirate or the same aspirate after freezing for one to six months. Gene expression and chromatin accessibility were compared between fresh and frozen samples by RNA-seq and ATAC-seq. Chromatin accessible regions were used to identify regulatory RNA expression in over 700 samples from newly diagnosed patients in the MMRF CoMMpass trial (NCT01454297). Results: Gene expression and chromatin accessibility of cryopreserved myeloma recapitulated that of freshly isolated samples. ATAC-seq performed on a series of biobanked specimens identified thousands of chromatin accessible regions with hundreds being highly coordinated with gene expression. Over 4,700 of these chromatin accessible regions were transcribed in newly diagnosed myelomas from the CoMMpass trial. Regulatory element activity alone recapitulated myeloma gene expression subtypes, and in particular myeloma subtypes with IGH translocations were defined by transcription of distal regulatory elements. Moreover, enhancer activity predicted oncogene expression implicating gene regulatory mechanisms in aggressive myeloma. Conclusions: These data demonstrate the feasibility of using biobanked specimens for retrospective studies of the myeloma epigenome and illustrate the unique enhancer landscapes of myeloma subtypes that are coupled to gene expression and disease progression.

2021-03-03 | GSE167967 | GEO

Multiple myeloma

Project description:Multiple myeloma

| PRJNA515992 | ENA